196 related articles for article (PubMed ID: 33540698)
1. Optimizing the Procedure to Manufacture Clinical-Grade NK Cells for Adoptive Immunotherapy.
Fernández A; Navarro-Zapata A; Escudero A; Matamala N; Ruz-Caracuel B; Mirones I; Pernas A; Cobo M; Casado G; Lanzarot D; Rodríguez-Antolín C; Vela M; Ferreras C; Mestre C; Viejo A; Leivas A; Martínez J; Fernández L; Pérez-Martínez A
Cancers (Basel); 2021 Feb; 13(3):. PubMed ID: 33540698
[TBL] [Abstract][Full Text] [Related]
2. How do we manufacture clinical-grade interleukin-15-stimulated natural killer cell products for cancer treatment?
Fernández L; Leivas A; Valentín J; Escudero A; Corral D; de Paz R; Vela M; Bueno D; Rodríguez R; Torres JM; Díaz-Almirón M; López-Collazo E; Martinez-Lopez J; Pérez-Martínez A
Transfusion; 2018 Jun; 58(6):1340-1347. PubMed ID: 29542132
[TBL] [Abstract][Full Text] [Related]
3. Optimization of Human NK Cell Manufacturing: Fully Automated Separation, Improved Ex Vivo Expansion Using IL-21 with Autologous Feeder Cells, and Generation of Anti-CD123-CAR-Expressing Effector Cells.
Klöß S; Oberschmidt O; Morgan M; Dahlke J; Arseniev L; Huppert V; Granzin M; Gardlowski T; Matthies N; Soltenborn S; Schambach A; Koehl U
Hum Gene Ther; 2017 Oct; 28(10):897-913. PubMed ID: 28810809
[TBL] [Abstract][Full Text] [Related]
4. GMP-Compliant Manufacturing of NKG2D CAR Memory T Cells Using CliniMACS Prodigy.
Fernández L; Fernández A; Mirones I; Escudero A; Cardoso L; Vela M; Lanzarot D; de Paz R; Leivas A; Gallardo M; Marcos A; Romero AB; Martínez-López J; Pérez-Martínez A
Front Immunol; 2019; 10():2361. PubMed ID: 31649672
[TBL] [Abstract][Full Text] [Related]
5. Novel treatment strategy with autologous activated and expanded natural killer cells plus anti-myeloma drugs for multiple myeloma.
Leivas A; Perez-Martinez A; Blanchard MJ; Martín-Clavero E; Fernández L; Lahuerta JJ; Martinez-Lopez J
Oncoimmunology; 2016; 5(12):e1250051. PubMed ID: 28123890
[TBL] [Abstract][Full Text] [Related]
6. Development of Automated Separation, Expansion, and Quality Control Protocols for Clinical-Scale Manufacturing of Primary Human NK Cells and Alpharetroviral Chimeric Antigen Receptor Engineering.
Oberschmidt O; Morgan M; Huppert V; Kessler J; Gardlowski T; Matthies N; Aleksandrova K; Arseniev L; Schambach A; Koehl U; Kloess S
Hum Gene Ther Methods; 2019 Jun; 30(3):102-120. PubMed ID: 30997855
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of serum-free media formulations in feeder cell-stimulated expansion of natural killer cells.
Moseman JE; Foltz JA; Sorathia K; Heipertz EL; Lee DA
Cytotherapy; 2020 Jun; 22(6):322-328. PubMed ID: 32278551
[TBL] [Abstract][Full Text] [Related]
8. Phase 2 Clinical Trial of Infusing Haploidentical K562-mb15-41BBL-Activated and Expanded Natural Killer Cells as Consolidation Therapy for Pediatric Acute Myeloblastic Leukemia.
Gómez García LM; Escudero A; Mestre C; Fuster Soler JL; Martínez AP; Vagace Valero JM; Vela M; Ruz B; Navarro A; Fernández L; Fernández A; Leivas A; Martínez-López J; Ferreras C; De Paz R; Blanquer M; Galán V; González B; Corral D; Sisinni L; Mirones I; Balas A; Vicario JL; Valle P; Borobia AM; Pérez-Martínez A
Clin Lymphoma Myeloma Leuk; 2021 May; 21(5):328-337.e1. PubMed ID: 33610500
[TBL] [Abstract][Full Text] [Related]
9. Expanded and Activated Natural Killer Cells for Immunotherapy of Hepatocellular Carcinoma.
Kamiya T; Chang YH; Campana D
Cancer Immunol Res; 2016 Jul; 4(7):574-81. PubMed ID: 27197065
[TBL] [Abstract][Full Text] [Related]
10. Activated and expanded natural killer cells target osteosarcoma tumor initiating cells in an NKG2D-NKG2DL dependent manner.
Fernández L; Valentín J; Zalacain M; Leung W; Patiño-García A; Pérez-Martínez A
Cancer Lett; 2015 Nov; 368(1):54-63. PubMed ID: 26276724
[TBL] [Abstract][Full Text] [Related]
11. Clinical-grade, large-scale, feeder-free expansion of highly active human natural killer cells for adoptive immunotherapy using an automated bioreactor.
Sutlu T; Stellan B; Gilljam M; Quezada HC; Nahi H; Gahrton G; Alici E
Cytotherapy; 2010 Dec; 12(8):1044-55. PubMed ID: 20795758
[TBL] [Abstract][Full Text] [Related]
12. [Method for expansion in vitro of CD3-CD56+CD16+NK cells highly purified from human peripheral blood].
Xiong D; Yang ZG; Li QH; Wu ZC; Lü JT
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Oct; 18(5):1310-5. PubMed ID: 21129283
[TBL] [Abstract][Full Text] [Related]
13. Ex vivo expansion of highly cytotoxic human NK cells by cocultivation with irradiated tumor cells for adoptive immunotherapy.
Lim SA; Kim TJ; Lee JE; Sonn CH; Kim K; Kim J; Choi JG; Choi IK; Yun CO; Kim JH; Yee C; Kumar V; Lee KM
Cancer Res; 2013 Apr; 73(8):2598-607. PubMed ID: 23580577
[TBL] [Abstract][Full Text] [Related]
14. Good manufacturing practice-compliant cell sorting and large-scale expansion of single KIR-positive alloreactive human natural killer cells for multiple infusions to leukemia patients.
Siegler U; Meyer-Monard S; Jörger S; Stern M; Tichelli A; Gratwohl A; Wodnar-Filipowicz A; Kalberer CP
Cytotherapy; 2010 Oct; 12(6):750-63. PubMed ID: 20491532
[TBL] [Abstract][Full Text] [Related]
15. Selection and expansion of natural killer cells for NK cell-based immunotherapy.
Becker PS; Suck G; Nowakowska P; Ullrich E; Seifried E; Bader P; Tonn T; Seidl C
Cancer Immunol Immunother; 2016 Apr; 65(4):477-84. PubMed ID: 26810567
[TBL] [Abstract][Full Text] [Related]
16. Carfilzomib combined with ex vivo-expanded patient autologous natural killer cells for myeloma immunotherapy.
Chang SK; Hou J; Chen GG; Yu DD; Wu HQ; Xie YS; Hu LN; Gao L; Xiao WQ; Kong YY; Tao Y; Shi JM
Neoplasma; 2018 Sep; 65(5):720-729. PubMed ID: 29940772
[TBL] [Abstract][Full Text] [Related]
17. The Synergistic Use of IL-15 and IL-21 for the Generation of NK Cells From CD3/CD19-Depleted Grafts Improves Their
Heinze A; Grebe B; Bremm M; Huenecke S; Munir TA; Graafen L; Frueh JT; Merker M; Rettinger E; Soerensen J; Klingebiel T; Bader P; Ullrich E; Cappel C
Front Immunol; 2019; 10():2816. PubMed ID: 31849984
[TBL] [Abstract][Full Text] [Related]
18. Closed-system manufacturing of CD19 and dual-targeted CD20/19 chimeric antigen receptor T cells using the CliniMACS Prodigy device at an academic medical center.
Zhu F; Shah N; Xu H; Schneider D; Orentas R; Dropulic B; Hari P; Keever-Taylor CA
Cytotherapy; 2018 Mar; 20(3):394-406. PubMed ID: 29287970
[TBL] [Abstract][Full Text] [Related]
19. Umbilical cord mesenchymal stem cells increase expansion of cord blood natural killer cells.
Boissel L; Tuncer HH; Betancur M; Wolfberg A; Klingemann H
Biol Blood Marrow Transplant; 2008 Sep; 14(9):1031-1038. PubMed ID: 18721766
[TBL] [Abstract][Full Text] [Related]
20. Ex vivo expansion of highly purified NK cells for immunotherapy after haploidentical stem cell transplantation in children.
Koehl U; Esser R; Zimmermann S; Tonn T; Kotchetkov R; Bartling T; Sörensen J; Grüttner HP; Bader P; Seifried E; Martin H; Lang P; Passweg JR; Klingebiel T; Schwabe D
Klin Padiatr; 2005; 217(6):345-50. PubMed ID: 16307421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
